Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide

Michael S. Bobola1, Douglas D. Kolstoe1, A. Blank1, Marc C. Chamberlain1,2 and John R. Silber1*

1 Department of Neurological Surgery, University of Washington Medical Center, Seattle, WA, USA
2 Department of Neurology, University of Washington Medical Center, Seattle, WA, USA

*Correspondence: jrsilber@u.washington.edu

INTRODUCTION
Methylating and chloroethylating agents have long been used in the adjuvant therapy of glioblastoma (GBM) and other malignant gliomas (Chamberlain, 2011). Inclusion of the methylator temozolomide (TMZ) during radiotherapy (RT) and continued administration of TMZ as a single agent afterward produces significant improvement in survival, marking a milestone in neuro-oncology (Stupp et al., 2009). Better outcome with concurrent TMZ-RT is associated with methylation of CpG dinucleotides in the promoter of the gene for O6-methylguanine-DNA methyltransferase (MGMT), indicative of silencing of expression of the sole human activity that removes O6-meG from DNA, is frequently associated with longer survival in GBMs treated with TMZ, promoting interest in developing inhibitors of MGMT to counter resistance. However, the clinical efficacy of TMZ is unlikely to be due solely to O6-meG, as the agent produces approximately a dozen additional DNA adducts, including cytotoxic N3-methyladenine (3-meA) and abasic sites. Repair of 3-meA and abasic sites, both of which are produced in greater abundance than O6-meG, is mediated by the base excision repair (BER) pathway, and occurs independently of removal of O6-meG. These observations indicate that BER activities are also potential targets for strategies to potentiate TMZ cytotoxicity. Here we review the evidence that 3-meA and abasic sites mediate killing of GBM cells. We also present in vitro and in vivo evidence that alkyladenine-DNA glycosylase, the sole repair activity that excises 3-meA from DNA, and Ape1, the major human abasic site endonuclease, mediate TMZ resistance in GBMs and represent potential anti-resistance targets.

Keywords: alkyladenine-DNA glycosylase, Ape1, apurinic endonuclease, DNA repair, treatment outcome, predictive marker

Alkylating agents have long played a central role in the adjuvant therapy of glioblastoma (GBM). More recently, inclusion of temozolomide (TMZ), an orally administered methylating agent with low systemic toxicity, during and after radiotherapy has markedly improved survival. Extensive in vivo and in vivo evidence has shown that TMZ-induced O6-methylguanine (O6-meG) mediates GBM cell killing. Moreover, low or absent expression of O6-methylguanine-DNA methyltransferase (MGMT), the sole human repair protein that removes O6-meG from DNA, is frequently associated with longer survival in GBMs treated with TMZ, promoting interest in developing inhibitors of MGMT to counter resistance. However, the clinical efficacy of TMZ is unlikely to be due solely to O6-meG, as the agent produces approximately a dozen additional DNA adducts, including cytotoxic N3-methyladenine (3-meA) and abasic sites. Repair of 3-meA and abasic sites, both of which are produced in greater abundance than O6-meG, is mediated by the base excision repair (BER) pathway, and occurs independently of removal of O6-meG. These observations indicate that BER activities are also potential targets for strategies to potentiate TMZ cytotoxicity. Here we review the evidence that 3-meA and abasic sites mediate killing of GBM cells. We also present in vitro and in vivo evidence that alkyladenine-DNA glycosylase, the sole repair activity that excises 3-meA from DNA, and Ape1, the major human abasic site endonuclease, mediate TMZ resistance in GBMs and represent potential anti-resistance targets.

Keywords: alkyladenine-DNA glycosylase, Ape1, apurinic endonuclease, DNA repair, treatment outcome, predictive marker

INTRODUCTION
Methylating and chloroethylating agents have long been used in the adjuvant therapy of glioblastoma (GBM) and other malignant gliomas (Chamberlain, 2011). Inclusion of the methylator temozolomide (TMZ) during radiotherapy (RT) and continued administration of TMZ as a single agent afterward produces significant improvement in survival, marking a milestone in neuro-oncology (Stupp et al., 2009). Better outcome with concurrent TMZ-RT is associated with methylation of CpG dinucleotides in the promoter of the gene for O6-methylguanine-DNA methyltransferase (MGMT), indicative of silencing of expression of the sole human activity that removes O6-meG from DNA, is frequently associated with longer survival in GBMs treated with TMZ, promoting interest in developing inhibitors of MGMT to counter resistance. However, the clinical efficacy of TMZ is unlikely to be due solely to O6-meG, as the agent produces approximately a dozen additional DNA adducts, including cytotoxic N3-methyladenine (3-meA) and abasic sites. Repair of 3-meA and abasic sites, both of which are produced in greater abundance than O6-meG, is mediated by the base excision repair (BER) pathway, and occurs independently of removal of O6-meG. These observations indicate that BER activities are also potential targets for strategies to potentiate TMZ cytotoxicity. Here we review the evidence that 3-meA and abasic sites mediate killing of GBM cells. We also present in vitro and in vivo evidence that alkyladenine-DNA glycosylase, the sole repair activity that excises 3-meA from DNA, and Ape1, the major human abasic site endonuclease, mediate TMZ resistance in GBMs and represent potential anti-resistance targets.

Keywords: alkyladenine-DNA glycosylase, Ape1, apurinic endonuclease, DNA repair, treatment outcome, predictive marker

Alkylating agents have long played a central role in the adjuvant therapy of glioblastoma (GBM). More recently, inclusion of temozolomide (TMZ), an orally administered methylating agent with low systemic toxicity, during and after radiotherapy has markedly improved survival. Extensive in vivo and in vivo evidence has shown that TMZ-induced O6-methylguanine (O6-meG) mediates GBM cell killing. Moreover, low or absent expression of O6-methylguanine-DNA methyltransferase (MGMT), the sole human repair protein that removes O6-meG from DNA, is frequently associated with longer survival in GBMs treated with TMZ, promoting interest in developing inhibitors of MGMT to counter resistance. However, the clinical efficacy of TMZ is unlikely to be due solely to O6-meG, as the agent produces approximately a dozen additional DNA adducts, including cytotoxic N3-methyladenine (3-meA) and abasic sites. Repair of 3-meA and abasic sites, both of which are produced in greater abundance than O6-meG, is mediated by the base excision repair (BER) pathway, and occurs independently of removal of O6-meG. These observations indicate that BER activities are also potential targets for strategies to potentiate TMZ cytotoxicity. Here we review the evidence that 3-meA and abasic sites mediate killing of GBM cells. We also present in vitro and in vivo evidence that alkyladenine-DNA glycosylase, the sole repair activity that excises 3-meA from DNA, and Ape1, the major human abasic site endonuclease, mediate TMZ resistance in GBMs and represent potential anti-resistance targets.

Keywords: alkyladenine-DNA glycosylase, Ape1, apurinic endonuclease, DNA repair, treatment outcome, predictive marker
Table 1 | Base adducts produced by 1-methylating agents.

| Major adducts                      | Percent | Biological effect | Repair          |
|------------------------------------|---------|-------------------|-----------------|
| 7-meG                              | 70      | Innocuous         | AAG             |
| 3-meA                              | 10      | Cytotoxic         | Poly(ADP-ribose) contact | AAG |
| O2-meG                             | 5–7     | Cytotoxic         | MGMT            |
| 1-meA                              | 2.8%    | Cytotoxic         | ABH2/ABH3       |
| 3-meC                              | 2.3%    | Cytotoxic         | ABH2/ABH3       |
| Minor adducts                      |         |                   |                 |
| 7-meA                              | 1.7     | Innocuous         | AAG             |
| 3-meG                              | 0.8     | Cytotoxic         | Poly(ADP-ribose) contact | AAG |
| O2-meT                             | 0.4     | Cytotoxic         | MGMT            |
| 1-meG                              | <1%     | Cytotoxic         | ABH2/ABH3       |
| 3-meT                              | <1%     | Cytotoxic         | ABH2/ABH3       |
| O2-meC                             | <1%     | Cytotoxic         | ?               |
| O2-meT                             | <1%     | Cytotoxic         | ?               |
| *Compiled from Barlow et al. (1993), Drabløs et al. (2004), Wyatt and Pittman (2006), Lee et al. (2009), and Shrivastav et al. (2010).

Cytotoxic ethano adducts, and inter-strand cross-links, including the cytotoxic-guanine cross-link produced by O6-chloroethylguanine (Ludlam, 1997).

As shown in Table 1, most methyl base adducts are implicated in promoting lethality, and cytotoxicity is strongly associated with blocked or interrupted DNA replication (Fu et al., 2012). Cytotoxic methyl adducts occur at positions on bases that are contacted by DNA polymerases (e.g., N3 of adenine) or are involved in Watson–Crick base-pairing (e.g., O6 of guanine). Lesions such as 3-meA prevent the contacts with critical amino acid residues in replicative DNA polymerases that are obligatory for synthesis (Flossky et al., 2008; Siddorova, 2008; Myers et al., 2009). Blocked replication forks are unstable and produce potentially cytotoxic double-strand breaks (DSBs) upon collapse. The commonly known lesion that disrupts base-pairing, O2-meG, does not block replication fork progression directly but allows incorporation of either cytosine or thymine, neither of which can correctly base-pair with the adduct (Roos and Kaina, 2012). The resulting mis-pair is recognized and the inserted base excised by the mismatch repair pathway, producing a long single-strand gap in newly synthesized DNA. Repair DNA synthesis to fill the gap produces another mis-pair, eliciting a futile cycle of excision and resynthesis, and the resulting single-strand gap produces a DSB during the next S-phase (Quiros et al., 2010). The resulting abasic sites are strong blocks to replication (Wilson and Bursky, 2003), and because of the preponderance of N-methyl adducts produced by methylating agents, are likely the most abundant potentially lethal lesion produced by TMZ.

REPAIR OF METHYL BASE ADDUCTS IN DNA

A number of DNA repair pathways promote GBM resistance to TMZ-induced base adducts. The best characterized of these is MGMT, which functions solely to restore O6-meG to guanine by transferring the methyl group to an internal cytosine residue (Silber et al., 2012). However, the most abundant TMZ-induced adducts, 7-meG, 3-meA, and abasic sites are excised from DNA by the short patch base excision repair (BER) pathway, a carefully coordinated, multi-step process that replaces a single nucleotide containing a damaged base (Fu et al., 2012). BER is an evolutionarily conserved repair pathway that primarily functions against endogenously generated DNA damage caused by the intrinsic instability of DNA and by oxidative metabolism (Robertson et al., 2009). The amount of such damage in normal cells is substantial with as many as 50,000 BER lesions formed daily. These spontaneously generated DNA adducts, including oxidized and alkylated bases, abasic sites, and single-strand breaks (SSBs), are identical to those generated by therapeutic ionizing radiation and many clinically utilized alkylating agents.

The BER of 3-meA and 7-meG is initiated by adduct recognition by AAG (also methylpurine-DNA glycosylase or alkylpurine-DNA-N-glycosylase) followed by cleavage of the glycosylase linkage between the damaged base and deoxyribose, producing an abasic site in DNA (Figure 1). AAG remains bound to the abasic site and recruits Ape1, the major human Ap endo (Abbotts and Madhusudan, 2010), which cleaves the DNA phosphodiester backbone to form a SSB with 3′-OH and 5′ deoxyribose phosphate (dRP) termini. Ape1 is then replaced by DNA polymerase β, a repair polymerase possessing a 5′-3′ polymerase activity that excises the 5′ dRP to yield a single nucleotide gap. The gap is filled by DNA polymerase β, leaving a strand break that is immediately sealed by DNA ligase III. The tightly coordinated mechanism of BER, necessary prevent accumulation of potentially lethal repair intermediates (i.e., abasic sites, 5′ dRP, SSB), is mediated by the protein XRCC1 which serves as a scaffold to foster the sequential action of each repair enzyme. In addition, poly(ADP-ribose) polymerase (PARP) facilitates repair by binding to SSBs and synthesizing long poly(ADP-ribose) chains that recruit XRCOC1, DNA polymerase β, and DNA ligase to the site of repair. The coordinated action of BER components is essential for methylator resistance, as evidenced by the increased cytotoxicity that accompanies unbalanced repair produced either by suppressed or enhanced expression of key elements (Fu et al., 2012).
Bobola et al. BER mediates GBM temozolomide resistance

Short patch BER is not the sole mechanism in human cells that promotes methylator resistance by removing N-methylated bases from DNA. 1-meA and 3-meC are demethylated in situ by the DNA dioxygenases ABH2 and ABH3 (Sedgwick et al., 2007). Other mechanisms promote tolerance of unrepaired lesions, e.g., translesion synthesis by Y family DNA polymerases (Plosky et al., 2008; Monti et al., 2010), replication restart at stalled forks (Blank et al., 2004), and rejoining of DSBs arising at sites of blocked DNA replication by homologous recombination and non-homologous end joining (Nikolova et al., 2010; Quiros et al., 2011). Full characterization of the contribution of these additional mechanisms to TMZ resistance in human gliomas awaits further study.

AAG PROMOTES RESISTANCE TO TMZ

Bacteria, yeast, and mammalian cells unable to excise 3-meA are hypersensitive to laboratory and clinically utilized methylating agents (Fronza and Gold, 2004; Wyatt and Pittman, 2006). Evidence that repair of 3-meA mediates alkylator resistance in human cancer cells has come from experiments in which AAG expression was suppressed and from studies using unique, sequence-specific alkylators that produce 3-meA as their sole cytotoxic lesion (Fronza and Gold, 2004). Below, we discuss the evidence that repair of 3-meA by AAG contributes to TMZ resistance in human GBM cells and tumors.

AAG SUBSTRATE SPECIFICITY AND PHYSIOLOGICAL ROLE

Alkyladenine-DNA glycosylase is one of 11 human DNA glycosylases characterized to date, and appears to be the primary activity that excises 3-meA and 7-meG from DNA (Fu et al., 2012). Unlike most DNA glycosylases, AAG has broad substrate specificity that includes oxidized and alkylated bases (Wyatt and Pittman, 2006). Hypoxanthine, a mutagenic deamination product of adenine, is the preferred substrate and is excised at least 1,000-fold more efficiently than alkyl adducts (O’Brien and Pittman, 2006). Hydroxymethylpurines, 3-meA is excised at a greater rate than 7-meG, and there is no evidence suggesting that AAG excises other methylated purines, or methylated pyrimidines in vivo. The catalytic activity of AAG against N-methylpurines is very modest in that, compared to spontaneous depurination, it reduces the half-lives for 3-meA and 7-meG in DNA only about a 1,000-fold (i.e., from hours to minutes), far less than the >10^20 rate enhancements yielded by most enzymes (O’Brien and Ellenberger, 2004). Excision of 7-meG, an innocuous adduct, by AAG to yield a cytotoxic abasic site could be a consequence of the broad substrate specificity of the enzyme; however, such excision may confer a selective advantage by preventing spontaneous depurination that would yield an unprotected abasic site. Of note, other AAG substrates include the DNA blocking adducts 1,N6-ethenoadenine and 1,N6-ethenoadenine produced by 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and cyclophosphamide, respectively, two agents used to treat recurrent GBMs (e.g., Chamberlain and TsaO-Wei, 2004; Stupp et al., 2007). Mice homozygous null for Aag are viable, develop normally and do not display enhanced rates of spontaneous carcinogenesis. However, Aag-/- animals and primary embryonic fibroblasts...
do show increased sensitivity to methylating agents (Engelward et al., 1998). In accord, suppressing AAG expression with siRNA produced hyper-sensitivity to TMZ and other alkylators in Hela and ovarian carcinoma cells (Pak et al., 2005). Yet, the importance of AAG in counteracting methylator genotoxicity in normal cells is not unambiguous, as evidenced by results showing that loss of activity is not necessarily accompanied by greater methylator sensitivity in some cell types (Wyatt and Pittman, 2006). For example, Aag−/− mouse myeloid bone marrow cells are more resistant to methylator-induced killing than wild-type cells, suggesting that excision of methyl adducts by AAG might promote killing. Notably, over-expression of AAG in rodent and human cancer cells increases sensitivity to methylators, including TMZ, that has been attributed to an imbalance in BER resulting in accumulation of cytototoxic abasic sites (e.g., Rinne et al., 2005; Tang et al., 2011). As discussed below, greater TMZ resistance accompanies high levels of AAG expression in human GBM tissue, indicating that unbalanced BER does not commonly accompany glial tumorigenesis.

**AAG PROMOTES TMZ RESISTANCE IN HUMAN GBM AND GLIOMA CELLS**

Early work from our laboratory strongly indicated that DNA adducts in addition to O6-meG cause TMZ cytotoxicity in human GBM cell lines, and that MGMT is not the only, or even the principal, agent of TMZ resistance (Bobola et al., 1996). We addressed this hypothesis directly by examining the sensitivity of a panel of 10 human glioma cell lines to methyl-lexitropsin (Me-Lex), a novel, sequence-specific alkylating agent that produces 3-meA as the predominant (i.e., > 90%) base adduct (Fronza and Gold, 2004). Suppressing AAG activity with antisense oligonucleotides (ASO) in MGMT-expressing, MGMT-deficient and MGMT- and mismatch repair-deficient GBM lines increased Me-Lex sensitivity assayed by survival of colony-forming ability (Bobola et al., 2007). Importantly, greater cell killing was accompanied by reduced content of abasic sites, the product of AAG-mediated excision of 3-meA. These finding provide strong evidence that unrepairred 3-meA is a potentially lethal lesion in human glioma cells and suggest that 3-meA plays a role in TMZ-induced cell killing.

Further evidence that TMZ-induced 3-meA contributes to cell killing was described in recent work examining the TMZ sensitivity of A172 cells, a human GBM cell line that has no detectable AAG or MGMT protein by Western blotting (Agnihotri et al., 2012). In these experiments variant lines were constructed that either expressed AAG alone, MGMT alone, or both repair activities. The variant line expressing AAG alone displayed elevated resistance to TMZ that was accompanied by decreased content of 7-methylguanine DNA methyltransferase (7-meG-DNMTase) relative to the repair-deficient parental line. Co-expression of AAG and MGMT resulted in yet greater TMZ resistance, consistent with independent contributions of AAG and MGMT to resistance. In complementary experiments, Agnihotri et al. (2012) showed that shRNA-mediated suppression of endogenous AAG increased sensitivity to TMZ in the GBM cancer stem cell line GBM2 and to methylmethanesulfonate (MMS), a methylator that produces very little O6-meG, in the GBM line T98G. More recently, our laboratory found that ASO-mediated suppression of AAG activity increased TMZ killing in MGMT-expressing, MGMT-deficient and MGMT- and mismatch repair-deficient GBM lines (Bobola et al., in preparation), providing additional evidence that TMZ-induced 3-meA promotes cytotoxicity in GBM cells. Elevated content of γ-H2AX, a surrogate marker for DSBs (Bonner et al., 2008), accompanied greater sensitivity to TMZ in ASO-treated cells, suggesting that unrepairred 3-meA is a precursor of lethal DSBs.

A role for AAG in TMZ resistance was further supported by examination of a panel of 19 xenografts established by intra-cranial implantation of human GBM tissue in nude mice (Agnihotri et al., 2012). AAG expression was undetectable by immunohistochemistry (IHC) in 11 of 19 (58%) xenografts, and absence of AAG was accompanied by significantly longer survival following treatment with TMZ. Comparable results were observed for survival of nude mice bearing intra-cranial xenografts derived from the A172 variant lines following treatment with TMZ, yielding strong evidence that 3-meA and O6-meG contribute independently to TMZ cytotoxicity. Interestingly, TMZ sensitivity was the same in variants expressing AAG alone or MGMT alone, suggesting that unrepairred 3-meA and O6-meG were equally cytotoxic.

A growing body of evidence indicates that TMZ is a radiosensitizing agent and that this property is partly responsible for the clinical efficacy of concomitant treatment with TMZ and radiation (Silber et al., 2012). Radiosensitization is most evident in MGMT-deficient GBM cells leading to the conclusion that failure to repair O6-meG promotes radiation sensitivity. In addition, we have reported that ASO-mediated suppression of AAG activity enhanced radiation killing in MGMT-expressing and MGMT- and mismatch repair-deficient GBM cells treated with minimally cytotoxic doses of TMZ (Bobola et al., 2010), indicating that 3-meA also promotes radiosensitization. Comparable increases in radiosensitivity were obtained when cells were exposed to Me-Lex, a methylator that produces almost exclusively 3-meA (Bobola et al., in preparation). In accord with these findings is the recent report that nude mice bearing AAG-deficient A172 xenografts survived significantly longer following concurrent treatment with TMZ and radiation compared to xenografts of AAG-expressing A172 variants (Agnihotri et al., 2012). These results strongly indicate that 3-meA as well as O6-meG contribute to TMZ-induced radiosensitization.

**AAG IN GLIOMA TISSUE AND ASSOCIATION WITH TREATMENT RESPONSE**

A number of studies have shown that gliomagenesis is accompanied by elevation of AAG expression as demonstrated by greater AAG mRNA content in gliomas relative to adjacent brain (Kim et al., 2000; Tang et al., 2011; Liu et al., 2012). IHC analysis of GBM and other gliomas revealed predominantly nuclear expression of AAG protein that displayed considerable inter-tumoral heterogeneity, with 20–30% of specimens having no detectable protein (Agnihotri et al., 2012; Liu et al., 2012). The analysis by Agnihotri et al. (2012) revealed that absence of detectable protein is associated with extensive methylation of promoter CpG islands, suggesting that AAG expression is epigenetically regulated in GBMs. Our recent analysis of AAG activity in 80 GBMs revealed...
AAG compared to tumors with shorter survival. These data sug-
the difference in risk of progression between the GBMs with

cin, contributing independently to resistance. In the bivariate model,
was also observed when AAG activity was entered as a continu-

sensitive to laboratory and clinically utilized methylating agents
as the cut point revealed a strong inverse trend between activity and

of the association of AAG biochemical activity with

tumors were treated with concurrent TMZ-RT. A dichotomous
set of tumor samples from the EORTC-NCIC trial (Stupp et al.,

Ape1 (also Ape1/Ref-1) is a multifunctional protein that is ubiqu-

Ape1 ENZYMATIC ACTIVITIES AND FUNCTION
Ape1 also participates in the regulation of calcium-dependent
gene expression and has roles in processing RNA and mRNA.
At least some of these Ape1-mediated functions are necessary for

Our laboratory has recently completed a preliminary exami-

progression-free survival (PFS) following alkylator treatment in
68 de novo GBMs that differed in activity by 820-fold. Forty-three

to TMZ-RT, regardless of MGMT promoter methylation status. That
this relationship reflected repair of TMZ-induced DNA damage was
evidenced by lack of an association between AAG expression
and survival in GBMs treated with radiation only.

Our laboratory has recently completed a preliminary exami-

Ape1 also has 5′-phosphodiesterase, 3′-phosphatase, and 3′-endo-

Ape1 PROMOTES RESISTANCE TO TMZ
Bacterial and yeast mutants lacking repair activities analogous to
human Ape1 and cells from Ape1 heterozygous mice are hyper-
sensitive to laboratory and clinically utilized methylating agents
(Evans et al., 2000; Abbotts and Madhusudan, 2010). Ape1 con-
tributes to methylator resistance in a variety of human tumor

tumors were treated with radiation followed by alkylator-based

sphere, including hypoxia and ionizing radiation, tran-

of the protein. The N-terminus of Ape1 is the redox protein Ref-1 that participates in response
to DNA damage-induced stress, cell cycle control and apoptosis
by maintaining critical transcription factors in an active, reduced
state. Ref-1 has also been implicated in regulating the transac-
tivation and proapoptotic functions of p53. Notably, exogenous
oxidative stress, including hypoxia and ionizing radiation, tran-
siently elevate Ape1 protein content and Ap endo activity and
increase alkylating agent resistance in human tumor cell lines (e.g.,

Ape1 PROMOTES RESISTANCE TO TMZ IN GBM CELLS
In early experiments, Ono et al. (1994) found that suppressing
Ap endo activity in rat glioma cells by using antisense expres-
sion constructs was accompanied by greater sensitivity to the
methylating agent MMS and to the oxidizing agent hydrogen
peroxide. In subsequent work, the same group reported that sen-
sitivity to MMS and hydrogen peroxide was inversely correlated
with Ap endo activity in a panel of human glioma-derived cell
lines (Ono et al., 1995). These experiments, however, provided
no information as to which Ape1 function promoted resistance.
To address this question and to further investigate the role
of Ape1 in alkylator resistance, we used anti-Ape1 ASO to show
that suppressing Ap endo activity in the MGMT-deficient human
GBM line SNB19 increased sensitivity to TMZ (Silber et al., 2002).
Ape1 expression has been the subject of intensive investigation, at least in part, to the potential of cell killing. Conversely, elevating Ap endo activity by exposing cells to minimally cytotoxic oxidative stress increased TMZ resistance and reduced abasic site content. Comparable effects on survival were observed for cells treated with the chloroethylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, carmustine). In subsequent experiments, we showed that suppression of Ap endo activity with anti-Ape1 ASO increased killing by the sequence-specific methylator Me-Lex in MGMT-proficient, MGMT-deficient, and MGMT- and mismatch repair-deficient GBM lines (Bobola et al., 2007). Increased cytotoxicity was accompanied by elevated abasic site content, indicating that lack of Ape1-mediated repair of abasic sites arising from excision of 3-mea promoted cell killing. Together, these two studies provide evidence that failure to excise abasic sites derived from TMZ-induced N-methylpurines contributes to GBM cell killing regardless of the ability to repair or tolerate O6-meG. A potential role for Ape1 in promoting resistance to adjuvant therapy in primary brain tumors in addition to GBM is supported by our findings that suppressing Ape1 expression and Ap endo activity increases the sensitivity of pediatric ependymoma cells to radiation (Bobola et al., 2011) and medulloblastoma cells to TMZ and BCNU (Bobola et al., 2005). In the latter case, TMZ sensitivity was also increased in MGMT- and mismatch repair-deficient medulloblastoma cells that are insensitive to the lethality of unpaired O6-meG.

Ape1 IN GLIOMA TISSUE AND ASSOCIATION WITH TREATMENT RESPONSE

Ape1 expression has been the subject of intensive investigation in a number of human cancers, including primary brain tumors (Bobola et al., 2004, 2005, 2011). In an initial study of human adult gliomas (Bobola et al., 2001), our laboratory assayed Ap endo activity in 84 tumors to establish correlates with tumor characteristics, and in histologically normal brain adjacent to 58 of the tumors to characterize changes in activity accompanying neurocarcinogenesis. Activity in all gliomas ranged ca. 550-fold and was, on average, 3.5-fold greater in anaplastic gliomas and GBMs than in low-grade tumors, suggesting that proliferation may be a determinant of activity. In accord, Ap endo activity was positively correlated with the fraction of S-phase cells. In the 58 cases of tumor paired with adjacent normal brain, mean activity was more than sevenfold higher in tumor than in normal tissue. Increased tumor activity was observed in 93% of tumor/normal pairs, indicating that elevation of Ap endo activity is characteristic of human gliomagenesis. The elevation was large in most pairs, being 13-fold on average and ≥ 10-fold in 43% of cases. A concomitant increase in Ape1 protein was observed by Western blotting in the subset of tumor/normal pairs examined. These findings suggest that the increase in Ap endo activity that accompanies gliomagenesis could enhance resistance to adjuvant therapy for GBM and other gliomas.

Numerous reports have described an inverse association between immunoreactivity for Ape1 and clinical course in a variety of human tumors (Evans et al., 2000; Abbotts and Madhusudan, 2010). To extend these studies to human gliomas and to evaluate Ap endo activity as a marker of treatment response, we examined the association of Ap endo activity with PFS following sequential treatment with radiation and alkylating agents in 30 anaplastic gliomas and 34 GBMs (Bobola et al., 2004). Cox regression analysis with Ap endo activity entered as a continuous variable revealed an inverse relationship with a HR for progression following alkylator therapy in the anaplastic gliomas increasing by a factor of 1.061 for every 0.01 increase in activity (P = 0.013). In contrast, we observed no association between activity and PFS in the GBMs, a result we attributed, in part, to the narrow range of PFS displayed by the tumors.

More recently, we have analyzed the association between Ap endo activity and PFS following treatment with alkylating agents in 80 de novo GBMs that differed in Ap endo activity by ≥ 225-fold (Bobola and Silber, in preparation). Sixty-four tumors were treated with radiation followed by alkylating agent-based chemotherapy and 16 were treated with concurrent TMZ-RT. A dichotomous Cox regression model revealed a twofold greater risk of progression (HR = 2.07; P ≤ 0.003) for tumors with greater than median Ap endo activity. Analyzing Ap endo as a continuous variable revealed that the risk of progression increased by a factor of 1.039 for every 0.01 unit increase in activity (P ≤ 0.022). In this group of GBMs, the difference in risk of progression between the tumor with the highest and lowest Ap endo activity was 3.3-fold. Analyses of 65 anaplastic gliomas that differed in Ap endo activity by 760-fold revealed a 2.1-fold greater risk for progression associated with activities greater than the median (P ≤ 0.022), and a 1.035 increase in risk for each 0.01 unit increase in activity (P ≤ 0.005) indicative of an 8.7-fold difference in risk between the tumors with the lowest and highest activities. These findings strongly indicate that Ap endo activity promotes resistance to alkylator agent therapy in GBMs and anaplastic gliomas. They also suggest that Ap endo activity may have utility as a marker of treatment response and is a potential target for anti-resistance therapies.

CIRCUMVENTING REPAIR OF ABASIC SITES TO REDUCE TMZ RESISTANCE

The association of DNA repair with clinical response to therapeutically DNA damaging agents has provided strong impetus to develop inhibitors of repair to improve treatment outcome. Characterization of inhibitors of MGMT (e.g., O6-benzylguanine, lomustine) and of PARP1 (e.g., olaparib, ABT-888) to circumvent resistance to TMZ are paradigms for this strategy (Mrugala and Chamberlain, 2009; Leonetti et al., 2012).

The role of Ape1 in promoting resistance to adjuvant therapy in GBM and other gliomas has stimulated interest in developing small molecule inhibitors targeting Ap endo activity (Wilson and Simeonov, 2010). Lucanthone, a DNA intercalator used to treat schistosomiasis (Basis and Mendez, 1997), was the first potential inhibitor identified. Lucanthone has been reported to inhibit incision at abasic sites by Ape1 in vitro and increase abasic site content in HeLa cells (Mendez et al., 2002), and to increase TMZ sensitivity in human breast cancer cells (Luo and Kelley, 2004) and human GBM cells (Silber and Bobola, unpublished observations). The mechanism of action was initially believed to involve drug intercalation that obscures abasic sites, but more recent evidence indicates that lucanthone can also inhibit nuclease activity of Ape1, which could increase abasic site content. Other inhibitors of repair include 5-aza-2′-deoxycytidine (5-aza-dC), a DNA methylation inhibitor that inhibits MGMT, and meta-chlorophenylhydrazine (mCP) and its active metabolite 4-hydroxyamino-2-methyl-6H-1,2,4-triazine-3,5(4H)-dione (lomustine), which block DNA repair pathways including BER (Mrugala et al., 2006). In GBM cells treated with mCP or lomustine, we showed that suppression of Ap endo activity with anti-Ape1 antibodies was associated with a 2.1-fold greater risk for progression following alkylator therapy in the anaplastic gliomas increasing by a factor of 1.039 for every 0.01 unit increase in activity (P ≤ 0.022). In this group of GBMs, the difference in risk of progression between the tumor with the highest and lowest Ap endo activity was 3.3-fold. Analyses of 65 anaplastic gliomas that differed in Ap endo activity by 760-fold revealed a 2.1-fold greater risk for progression associated with activities greater than the median (P ≤ 0.022), and a 1.035 increase in risk for each 0.01 unit increase in activity (P ≤ 0.005) indicative of an 8.7-fold difference in risk between the tumors with the lowest and highest activities. These findings strongly indicate that Ap endo activity promotes resistance to alkylator agent therapy in GBMs and anaplastic gliomas. They also suggest that Ap endo activity may have utility as a marker of treatment response and is a potential target for anti-resistance therapies.
that lucanthone acts, at least in part, by binding to the active site of Ape1 (Naudo et al., 2011). Lucanthone has also been shown to sensitize brain metastases to radiation (Del Rowe et al., 1999). On the basis of this sensitization, together with demonstrated safety and ability to cross the blood brain barrier (Del Rowe et al., 1999), lucanthone is currently in phase II trial (NCT01587144) to evaluate safety and efficacy in GBMs treated with concurrent TMZ-RT.

Ongoing investigation using high-throughput screening coupled with molecular modeling of active site binding has identified a large number of potential small molecule inhibitors of Ape1-catalyzed Ap endo activity (Bapst et al., 2010b; Wilson and Simoonsov, 2010; Mohammed et al., 2011; Rai et al., 2012). While all of these compounds inhibit Ap endo activity in vitro, only a limited number have been shown to sensitize cells to TMZ. Madhusudan et al. (2005) identified inhibitors from a library of over 2.5 million compounds (e.g., 7-nitro-indole-2-carboxylic acid) that sensitized fibrosarcoma and GBM cells to MMS and TMZ. Madhusudan et al. (2005; Mohammed et al., 2011). Bapat et al. (2010) identified four potential inhibitors, including one (AR03) that elicited hypersensitivity to MMS and TMZ in the malignant glioma line SF767. Both groups reported that methylator hypersensitivity was accompanied by elevated abasic site content, affording evidence of inhibition of Ap endo activity in vivo. More recently, a series of Ape1 Ap endo inhibitors based on 2-methyl-4-amino-6,7-dioxolo-quinoline was shown to increase sensitivity to the methylator Me-Lex and to consistently increase abasic site content in the human GBM line T98G (Srinivasan et al., 2012). Also, Rai et al. (2012) have described synthesis and characterization of the inhibitor, N-(3-(benzoyl)thiao)2-yl)-4-isopropyl]-1,6,7 triarylthiazol[2,3-c]pyridin-2-yl)acetamide that sensitized HeLa cells to MMS and TMZ. Of note, this lipophilic compound readily crossed the blood-brain barrier of mice, satisfying one requirement for efficacy in treating human gliomas.

To our knowledge there are no small molecule inhibitors of AAG in development. However, the advent of site-specific methylators that produce 3-meA at abasic sites in the human GBM line T98G (Fronza and Gold, 2004) suggest that it may be possible to induce numbers of adducts that are sufficient to overwhelm tumor cell repair capacity.

CONCLUSIONS AND FUTURE CONSIDERATIONS

The demonstration that MGMT promoter methylation status is associated with GBM response to TMZ-based therapies highlights the potential importance of DNA repair in determining clinical course (Silber et al., 2012). However, methylation status does not accurately predict treatment response in the majority of GBMs, suggesting that MGMT is not the sole, or even the predominant, determinant of therapeutic response. As set out in this review, there is now increasing evidence that AAG and Ape1 also promote resistance in GBMs treated with TMZ and other alkylators, supporting the multifactorial nature of DNA repair-mediated treatment failure in GBMs. The clinical relevance of repair of 3-meA and abasic sites is illustrated in Table 2 which documents our finding that the association of tumor AAG and Ap endo activities with alkylating agent response is comparable to that of MGMT.

The goal now is to translate this knowledge into more effective treatments for GBM.

The emerging data reviewed here suggest that that AAG and Ape1 may have utility as markers of clinical response to TMZ-based adjuvant therapy. Inclusion of AAG and/or Ape1 together with MGMT expression in multivariate models may allow more accurate prediction of clinical response and further the goal of individualizing treatment for GBM, an expectation supported by the stratification of survival based on AAG immunopositivity in both MGMT promoter methylated and unmethylated GBMs (Agiolohiti et al., 2012). Realizing this goal will require development of clinically tractable assays for these proteins. Assays of AAG and Ape1-mediated Ap endo activity is not currently practical for routine clinical laboratory use. IHC and surrogate measures of gene expression, such as promoter methylation status, have the advantage of using fixed tissue as starting material. In the case of AAG, both of these approaches may be efficacious, as evidenced by the stratification of survival based on AAG immunopositivity mentioned above, and initial evidence that AAG expression is inversely associated with methylation of promoter CpG islands (Agiolohiti et al., 2012). Ape1 expression is particularly attractive as a marker of GBM clinical outcome because of its multiple DNA repair and non-repair functions that promote resistance to radiation as well as alkylating agents (Abbotts and Madhusudan, 2010). Numerous studies have associated Ape1 immunopositivity with clinical response in a variety of human cancers, suggesting that this measure may prove useful in GBM and other adult gliomas.

AAG and Ape1 are also attractive targets for anti-resistance therapies to enhance the effectiveness of TMZ and other alkylators. As discussed, suppressing AAG or Ape1 expression is accompanied by greater alkylator sensitivity in human GBM cells regardless of their ability to repair or tolerate cytotoxic O6-meG. The development of small molecule inhibitors of the Ap endo activity of AAG and of sequence-specific alkylators that produce 3-meA as the sole cytotoxic lesion are active areas of investigation. The promising recent results suggesting the potential of these strategies to improve clinical outcome must be tempered by the difficulty in translating preclinical findings with GBM cells into effective human therapies. Clinical utilization requires circumventing numerous pharmacological limitations, including stability, solubility, excretion,
and ability to penetrate physiological barriers. In addition, sys-
tematic administration of inhibitor molecules increases the risk of producing unacceptable off-target toxicity that leads to efficacy-
compromising alkylation dose reductions. Circumventing these
problems will require pharmacologically compatible delivery vehi-
cles that sequester inhibitor during transit, penetrate the blood-
brain barrier and specifically target tumor cells. Prototypes of such
agents have been described, but this area of research is still in its
infancy.

ACKNOWLEDGMENTS
This work was supported by funding from the NIH (CA104593,
CA10987, and CA131638) and a gift to the Brain Tumor Research
Fund in memory of Ro Jean Mount.

REFERENCES
Agnihotri, S., and Madhusudan, S. (2010). Human AP endonuclease 1
(APE1) from mechanistic insights to druggable target in cancer.
Cancer Treat Rev. 36, 425–435.
Agthiourn, S., Gadallah, A. S., Ta-
namian, C., Gofia, T., Defos, K. L., Nossich, P., et al. (2012).
Alkylation-resistant N-glycosylase
confers resistance to temozolomide in xenograft models of glioblastoma
multiforme and is associated with poor survival in patients. J. Clin.
Cancer Res. 22, 235–266.
Bapat, A., Glass, L. S., Luo, M., Fishel,
M. S., et al. (2010). Novel small-molecule inhibitors of apurinic/apyrimidinic
endonuclease 1 block proliferation and reduces viability of glioblastoma
cells. J. Pharmacol. Exp. Ther. 334, 988–998.
Baos, R. E., and Mendel, F. (1997). Tietoposensory inhibition by la-
caine, an anesthetic in radiation ther-
apy. Int. J. Radiat. Oncol. Biol. Phys. 37, 1133–1137.
Bonafe, D. (1990). Distribution of methyl and ethyl adducts follow-
ing alkylation with monofunctional
alkylating agents. Mutat. Res. 231, 11–30.
Bonnar, M. S., Bobola, M. S., Gold,
B., Vartanian, S., Kolstoe, D. D., Blank,
A., and Silber, J. R. (2010). Mini-
mal changes in AKT and PI3K signaling in glioblastoma. Mol. Cancer Ther.
9, 1133–1137.
Bobola, M. S., Finn, L. S., Ellenbo-
ny, R., Sood, B., Filippi, C., Moran,
R., Saito, H., et al. (2005). Two essential
endonuclease inhibitors in melanoma and is associated with
response to radiation and chemotherapy in multiforme and is associated
with poor survival in patients. J. Clin.
Cancer Res. 11, 7405–7414.
Bobola, M. S., Vartanian, S., Smith, N. W., Gerli, R. D., Kolstoe, D. D., Blank,
A., et al. (2007). Human glioma cell sensitivity to the sequence-
specific alkylating agent methyl-
leucostine. Clin. Cancer Res. 13, 612–620.
Bobola, M. S., Kolstoe, D. D., Blank,
A., and Silver, J. B. (2010). Muta-
ntype cytosine dous of tenuolomade
produce radiosensitization in human glioblastoma cells regardless
do not compromise the therapeutic effects of pemetrexed
base-excision repair, to potentiate
DNA damage in glioblastoma.
Front. Oncol. 2, 579–584.
Braun, M. S., Iwakura, P. F., Gross,
M. S., et al. (2010). Apurinic/apyrimidinic
endonuclease is inversely associated
with response to radiation therapy in pediatric ependymoma. Int. J. Cancer
126, 2570–2579.
Bromberg, K. J., and Silver, J. B. (2010). Apurinic/apyrimidinic
endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neu-
roectodermal tumors. Clin. Cancer Res.
16, 104–120.
Brow, M. E., Dunnm, A. C., Gerli, T., Hamset, M. F., de Tiffiet, N., Weiler,
M., et al. (2005). MGMT gene silenc-
ing and benefit from temozolomide in glioblastoma. Nat. Engl. J. Med. 352, 995–1005.
Brown, M. S., Frey, M. J., Blank, A.,
Mendel, D. S., Karaman, R. K., Goldmahl, B., et al. (2006). A phase 1 study of oral TRC102
(polybromoarylamine), an inhibitor of base-excision repair, to potentiate
the therapeutic effects of penitomycin in patients with advanced refractory
malignancy. Mol Cancer Ther 5(Suppl. 1),
B62.
Inoue, T., Broos, D. R., Naidis, C.
V., Bhatar, R. K., Macias, M., Aita,
H., et al. (2005). Two essential but distinct functions of the mamm-
al alkyltransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 102, 5793–5798.
Kim, K. N., Ahn, J. Y., Song, J., Kim,
J. K., Han, J. H., An, H. J., et al. (2003). Expression of the DNA repair
enzyme, N-methylpurine-DNA glyco-
lyase (MPG) in astrocytic tumors. Brain Pathol. 13, 1475–1479.
Lee, C. Y., Yoon, J. C., Ko, J., Kang,
J., Pyo, K., et al. (2003). Alkylation of
N6-methylguanine DNA glyco-
lyase (MPG) in astrocytic tumors. Brain Pathol. 13, 1475–1479.
Myers, K., Gago, M. E., Zanetta-Villar, P., Rodrigues, R., and Meuth, M. (2008). ATR and Chk1 suppress a cancer-cell-dependent apoptotic response following DNA replication stress. *PLoS Genet.* 5, e1000524. doi: 10.1371/journal.pgen.1000524

Naidle, M. D., Agarwal, R., Pena, L. A., Camba, L., Moen, M., Shen, M., et al. (2011). Lacazamone and its derivative brexamac inhibits apurinic endonuclease-1 (APE1) by direct protein binding. *PLoS ONE* 6, e22679. doi: 10.1371/journal.pone.0022679

Nikolaou, T., Euminnger, M., Lobrich, M., and Kaina, B. (2010). Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate. *DNA Repair* 9, 1080–1086.

O’Brien, P. J., and Ellingtoner, T. (2014). Dissecting the broad substrate specificity of human 3-methyladenine-DNA glycosylase. *J Biol. Chem.* 289, 9750–9757.

Ono, Y., Furuta, T., Ohmoto, T., Akiyama, K., and Seki, S. (1994). Staurosporine- and staurosporine-1 inhibitors. *J. Med. Chem.* 37, 315–322.

Shrivastav, N., Li, D., and Essigmann, J. M. (2010). Chemical biology of DNA polymerase beta modulate BER activity of Ape1/Ref-1 inhibitors. *PLoS ONE* 5, e1000324. doi: 10.1371/journal.pone.0010003

Sedgwick, B. (2005). Sensitization of mammalian cells from replication-associated DNA double-strand break repair of 3-alkyladenine-DNA lesions by small interfering RNA. *J. Biol. Chem.* 280, 471–486.

Srinivasan, A., Wang, L., Cline, C. J., Xie, Z., Sobol, R. W., Xie, X. Q., et al. (2012). The identification and characterization of human AP endonuclease 1 inhibitors. *Biochemistry* 51, 6326–6339.

Stupp, R., Hegi, M. E., Gilbert, M. R., and Chakravarti, A. (2005). Chemoradiation therapy in malignant glioma: standard of care and future directions. *J. Clin. Oncol.* 23, 4127–4136.

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J.; on behalf of the European Organisation for Research, and Treatment of Cancer Brain Tumour, and Radiation Oncology Groups; the National Cancer Institute of Canada Clinical Trials Group. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study. 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol.* 10, 459–465.

Tang, J. B., Brik, D., Trivedi, R. N., Wang, X. H., Goellner, E. M., Moore, B., et al. (2011). N-methylguanine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cell toxicity. *Neuro Oncol.* 13, 471–481.